Early effects of sodium valproate monotherapy on serum paraoxonase/ arylesterase activities

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 1, 2009, Pages 31-35

  Karikas, George A ^a   Schulpis, Kleopatra H ^b   Bartzeliotou, Anastasia ^c   Regoutas, Spyros ^c   Thanopoulou, Christina ^c   Papaevangelou, Vassiliki ^c   Giannoulia Karantana, Aglaia ^b   Papassotiriou, Ioannis ^c   Fytou Pallikari, Athena ^a  

^a UNIVERSITY OF WEST ATTICA   (Greece)

^b Institute of Child Health Athens gr   (Greece)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Arylesterase; Free radicals; Paraoxonase1; Valproate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FREE RADICAL; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALPROIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BENIGN CHILDHOOD EPILEPSY; BLOOD CHEMISTRY; CHEMICAL ANALYSIS; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LABORATORY TEST; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LIPIDS; MALE; OXIDANTS; SEIZURES; VALPROIC ACID;

TOSCANA VIRUS;

EID: 61649118439     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510802248051     Document Type: Conference Paper

References (29)

1. Garcia-Morales I, Rieger JS, Gil-Nagel A, Fernadez JLH. Antiepileptic drugs: scientific evidence to clinical practice. Neurologist 2007;13 Suppl 1:S20-8.
2. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorders. Am J Psychiatry 1990;147:431-4.
3. Shelton CE, Connelly JF. Valproic acid a migraine prophylaxis alternative. Ann Pharmacother 1996;30:865-6.
4. Levy RH. Antiepileptic drugs, 5th edn. Philadelphia: Lippincott Williams and Wilkins, 2002. p. 843-5.
5. Gilfum-Sherki Y, Rosenbaum Z, Mclamed E, Oflen D. Antioxidant therapy in acute central nervous system injury. Curr State Pharmacol Rev 2000;54:271-84.
6. Finker T, Holbrook NJ. Oxidants, oxidative stress and the biology of aging. Nature (Lond) 2000;408:239-47.
7. Sonmez FM, Demir E, Orem A, Yildirmis S, Orhan F, Aslan A, et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein(a) and liver enzymes. J. Child Neurol 2006;21:70-4.
8. Tekgul H, Demir N, Gokben S. Serum lipid profile in children receiving anti-epileptic drug monotherapy: Is it atherogenic? J Pediatr Endocrinol Metab 2006;19:1151-5.
9. Voudris KA, Attilakos A, Katsarou E, Drakatos A, Dimou S, Mastroyiannis S, et al. Early and persistent increase in serum lipoprotein(a) concentration in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res 2006;70:211-17.
10. Schulpis KH, Lazaropoulou C, Regoutas S, Karikas GA, Margeli A, Tsakiris S, et al. Valproic acid monotherapy induces DNA oxidative damage. Toxicology 2006;217:228-32.
11. La Du BN. Structural and functional diversity of paraoxonases. Natural Medicine 2, 1996;1186-7.
12. Josse D, Lockridge O, Xie W, Bartels CF, Schopfer LM, Masson P. The active site of human paraoxonase (PON1). J Appl Toxicol 2001;21 Suppl:57-511.
13. Nguyen DS, Sok DE. Oxidative inactivation of paraoxonase 1, an antioxidant protein and its effect on antioxidant action. Free Rad Res 2003;37:1319-30.
14. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. Paraoxonase active site required for protective against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities; selective action of human paraoxonase alloenzymes Q and R. Arterioscler Thromb Vasc Biol 1998;18:1617-24.
15. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase1, is the oxidized phospholipids hydrolase of high density lipoprotein particles. J Biol Chem 2003;278:3937-47.
16. Schulpis KH, Tsironi M, Skenderi K, Lazaropoulou C, Parthimos N, Reclos G, et al. Dramatic reduction of erythrocyte glucose-6-phosphate dehydrogenase activity in athletes participating in the ultradistance foot race "Spartathlon". Scand J Clin Lab Invest 2007;12:1-7.
17. Charlton-Menys V, Liu Y, Durrington PN. Semiautomated method for determinations of serum paraoxonase activity using paraoxon as substrate. Clin Chem 2006;52:453-7.
18. Schulpis KH, Bartzeliotou A, Tsakiris S, Gounaris A, Papassotiriou I. Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet. Eur J Clin Nutr 2007;61:803-8.
19. Bryan AE, Dreifuss FE. Valproic acid hepatic fatalities USA experience since. Neurology 1996;46:465-9.
20. Jeavons PM. Non-dose-related side effects of valproate. Epilepsia 1984;25:55-6.
21. Tong V, Chang TK, Chen J, Abbott FS. The effect of valproic acid on hepatic and plasma levels of 15-F2t-isoprostane in rats. Free Radic Biol Med 2003;34:1435-46.
22. Halliwell B, Gutlerdge JMC. Free radicals in biology and medicine, 2nd edn. Oxford: Clarendon Press, 1989. p. 110-19.
23. Simon HU, Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptotic induction. Apoptosis 2000;5:415-18.
24. Karikas GA, Shulpis KH, Barzeliotou A, Karakonstantakis T, Georgala S, Kanavaki I, et al. Lipids, lipoproteins, apoliproteins, selected trace elements and minerals in children on valproic acid monotherapy. Basic Clin Pharmacol Toxicol 2006;98:599-603.
25. Ferre N, Camps J, Cabre M, Paul A, Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 2001;9:997-1000.
26. Ferre N, Camps J, Prats E, Villela E, Paul A, Figuera L, et al. Serum paraoxonase1 activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002;48:262-8.
27. Heinecke JW, Lusis AJ. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 1998;62:20-4.
28. Gur M, Yildiz A, Demirbag R, Yilmaz R, Aslan M, Ozdogru I, et al. Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and their relationship with oxidative stress markers. Coronary Artery Dis 2007;18:89-95.
29. Schulpis KH, Karikas GA, Tjamourakis J, Tsakiris S. Low serum biotinidase activity in children with valproic acid monotherapy. Epilepsia 2001;56:912-14.